IN8bio, Inc. (INAB)

Market Cap	23.30M
Revenue (ttm)	n/a
Net Income (ttm)	-31.88M
Shares Out	72.48M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,800
Open	0.317
Previous Close	0.317
Day's Range	0.306 - 0.322
52-Week Range	0.217 - 2.480
Beta	-0.07
Analysts	Strong Buy
Price Target	7.75 (+2,310.58%)
Earnings Date	Nov 12, 2024

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: INAB
• Website: https://in8bio.com

Analyst Forecast

According to 3 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $7.75, which is an increase of 2,310.58% from the latest price.

Price Target

$7.75

(2,310.58% upside)

Analyst Consensus: Strong Buy